RAJA THIRUMALAIRAJ

Senior Consultant Medical Oncologist & Bone Marrow Transplants. Conferred “Best Doctor Award” by 'Tamil Nadu Dr.MGR Medical University’

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@tompowles1 Are we okay in choosing this in platinum eligible also. Push EV 303 a little further. Say if patient does not like chemo.

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@OncBrothers @US_FDA @stolaney1 @drsarahsam @dr_yakupergun @ErikaHamilton9 @PTarantinoMD @AbiSivaMD @jamecancerdoc @SPremji7866 @BijoyTelivala @AMJohnston1315 How to integrate this into Her2CLIMB 05 presented in ASCO 2026. In patients who are ER negative Tucatinib. If ER positive take PATINA route and add endocrine.

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@DrRishabhOnco Matterhorn allowed T2, had 50% less Diffuse histology and had more Caucasian ethnicity. I believe these things MATTERED.

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@SuyogCancer MIRV is not the culprit. The setting was not right. MIRASOL showed that MIRV can work better in Plat refractory. I believe we should look at first line option treatment naive option to combine with platinum.

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@SuyogCancer @myESMO @SuyogCancer Can we get the curves for pMMR ? And what do we take away from RUBY part 2.

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@ChandrakanthMv Switch maintanance !! Same concept as established in Lung, Bladder etc. Can we say that Tucatinib is best only for ER negative. If ER positive you do better with Endocrine therapy aka PATINA.

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@ChandrakanthMv Can we simply say: 1) Prognostic: You can guess the future but cant change it. 2) Predictive: You can guess the future, and change it. Quote: "You can't change your past, but can change your future"

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@OncBrothers @NiuSanford @UTSW_RadOnc @jryckman3 @SuyogCancer @dr_yakupergun @MKnoll_MD @DrewMoghanaki @JasmineKambojMD @radoncreview @GlopesMd @BijoyTelivala That was an insightful discussion. We are mostly careful to integrate chemo or systemic onco therapies with RT. However, we should not forget that routine drugs like antioxidant supplements, and certain NSAIDs also need to be checked.

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@weldeiry Professor El Deiry's lecture was one of the highlights of the Mumbai meeting. Amazing work with WIN consortium. Thanks for enlightening us. Pioneering fight (flight) across Precision (pacific) ocean. 🙏

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@ChandrakanthMv Cant deny the superiority. Almost like winning with > 50 runs in a T20 Match. However, once the placebo arm is read out we will know the real match winner or anchor. Also 12% ILD is really a big concern. The next big unmet need is ILD prophylaxis if possible.

[RAJA THIRUMALAIRAJ @RAJATRAJ]

We welcome you all to present your original data in front of International Faculty. Global audience. 🙏

[RAJA THIRUMALAIRAJ @RAJATRAJ]

Welcome everyone 🙏

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@SuyogCancer Exactly. But, I’m wondering if this will be a better. even in cisplatin eligible patients. That’s what we learn from EV302.

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@bmtdoc63 @JanakiramMurali @bmtdoc63 It would be our privilege to have you with us. Certainly Cell therapy will be a big part of the agenda. 🙏

[RAJA THIRUMALAIRAJ @RAJATRAJ]

I take the pleasure to invite the global oncology fraternity for the forthcoming Indian cancer congress 2027, which is the largest gathering of the Indian oncology community. Welcome. 🙏🙏

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@nihardesai89 @nihardesai89 Thank you. The ICC 2027 will have a strong academci agenda, with 12 to 16 tracks and more than 200+ sessions over 4 days. 🙏

[RAJA THIRUMALAIRAJ @RAJATRAJ]

@JanakiramMurali It will be amazing to have you with us @JanakiramMurali We shall have dedicated sessions on CAR T, and Myeloma. So much to catch up.

[RAJA THIRUMALAIRAJ @RAJATRAJ]

The Indian Cancer Congress 2027 will be led by these eminent men and women. This will showcase Indian Oncology at its best. Invite the global oncology fraternity to be with us. Aspire to learn from each other. 🙏🙏